Introduction:
Hip fragility fractures are costly, catastrophic, and are associated with high mortality
rates. One treatment to lower hip fracture risk uses a minimally-invasive local osteo-enhancement
procedure (LOEP) to deliver a novel triphasic calcium sulfate/calcium phosphate implant
material (AGN1) into the proximal femur, with the intent of increasing femoral strength
by regenerating bone lost due to osteoporosis. The purpose of this study was to evaluate
the Finite Element Analysis (FEA) estimated femoral strength of postmenopausal osteoporotic
women treated with the procedure.
Methods:
One proximal femur from each of 12 post-menopausal osteoporotic women was treated
with AGN1 LOEP and the non-treated femurs served as the control. CT scans were taken
preoperatively and at 12 weeks (N = 12), 24 weeks (N = 12), and an average of 315
weeks (5 – 7 years) (N = 10). Patient-specific, non-linear FEA was conducted to non-invasively
estimate hip strength in simulated sideways fall and stance loading conditions (O.N.
Diagnostics, Berkeley, CA). A scale factor was applied assuming either 100% (α= 1.0)
or, conservatively, 30% (α= 0.30) of new tissue performed as normal, load-bearing
bone.
Results:
Mean patient age was 72 years old (range 56 – 89). At baseline, T-scores of the treated
and control hips were identical (-3.1 ± 0.5 and -3.0 ± 0.7). Regardless of assumed
scale factor, femoral strength in sideways fall was substantially higher in treated
than in control hips. At 12 weeks, hip strength increased by 63 ± 32% (α= 1.00) and
45 ± 30% (α= 0.30) (p < 0.01). At 24 weeks, hip strength increased by 58 ± 27% (α=
1.00) and 40 ± 25% (α= 0.30) (p < 0.01). At 315 weeks, hip strength increased by 37
± 15% (α= 1.00) and 23 ± 15% (α= 0.30) (p < 0.01). Stance loading effects were statistically
significant across all time points with α= 1.00 only (p < 0.01). Mechanistically,
at early time points newly formed bone adjacent to the implant area provided additional
pathways for load transfer. At 315 weeks, the analysis suggests there is new integrated
load-bearing bone within the treatment region.
Discussion:
These results suggest that AGN1 LOEP treatment of the proximal femur in osteoporotic
women can substantially increase proximal femoral strength for sideways fall and this
benefit is apparent soon after treatment and persists for at least 5 – 7 years.